Harvard turns to Evotec again to add value to early stage assets
This article was originally published in Scrip
Executive Summary
Evotec of Germany has entered a second alliance with Harvard University in the US, this time in the field of kidney disease. Evotec's ongoing alliance with Harvard is focused on diabetes and is aimed at bolstering early stage academic assets to get them ready for out-licensing.